Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | GRM5 | P41594 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12146426 | 0.84 | GRM5 (0.43) | PKMALDH1A1GRM5KDM4EKMT2A | |
| SCHEMBL305742 | 0.81 | ALDH1A1 (0.44) | ALDH1A1GRM5POLBKMT2ARAB9A | |
| SCHEMBL18730881 | 0.80 | ADORA2B (0.46) | ALDH1A1GRM5KDM4EPOLBKMT2A | |
| SCHEMBL18901777 | 0.76 | ALDH1A1 (0.41) | ALDH1A1GRM5KDM4EPOLBKMT2A | |
| SCHEMBL13145415 | 0.76 | CTSK (0.39) | ALDH1A1GRM5KDM4EPOLBRAB9A | |
| SCHEMBL753231 | 0.74 | DYRK1A (0.43) | ALDH1A1KDM4EPOLBNPC1RAB9A | |
| SCHEMBL14723766 | 0.74 | ALDH1A1 (0.40) | ALDH1A1KDM4EPOLBHPGDL3MBTL1 | |
| SCHEMBL13389771 | 0.73 | TSHR (0.39) | ALDH1A1GRM5KDM4EPOLBNPC1 | |
| SCHEMBL755948 | 0.72 | ALDH1A1 (0.43) | ALDH1A1KDM4EPOLBKMT2AHPGD | |
| SCHEMBL13379438 | 0.71 | TSHR (0.38) | ALDH1A1GRM5KDM4EPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| EP-2601188-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-18 | — | — | EP | disclosed |
| US-9776981-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| US-9776981-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| EP-2328865-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-2513091-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-04-12 | — | — | EP | disclosed |
| EP-2499132-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-02-15 | — | — | EP | disclosed |
| EP-2499115-B1 | PROCESS FOR PREPARING HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB HOLDINGS IRELAND (CH) | 2016-07-27 | — | — | EP | disclosed |
| US-9303007-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-05 | — | — | US | disclosed |
| US-20100068176-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-18 | — | — | US | disclosed |
| US-20090233925-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-17 | — | — | US | disclosed |
| US-20090233925-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-17 | — | — | US | disclosed |
| WO-2009102694-A1 | HETEROCYCLIC DERIVATIVES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-20 | — | — | WO | disclosed |
| WO-2009102633-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-20 | — | — | WO | disclosed |
| WO-2009102568-A1 | CONFORMATIONALLY RESTRICTED BIPHENYL DERIVATIVES FOR USE AS HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-20 | — | — | WO | disclosed |
| US-20090202483-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-08-13 | — | — | US | disclosed |
| US-20090202483-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-08-13 | — | — | US | disclosed |
| US-20090202478-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-08-13 | — | — | US | disclosed |
| US-20090202478-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | HAVCR2, LIPC, PYGL | PKM 3877/4885ALDH1A1 1107/4885GRM5 3762/4885 |
| US-20100068176-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | PKM 3874/4885ALDH1A1 1144/4885GRM5 3907/4885 |
| US-20090202478-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | PKM 3874/4885ALDH1A1 1144/4885GRM5 3907/4885 |
| US-20090233925-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | PKM 3874/4885ALDH1A1 1144/4885GRM5 3907/4885 |
| US-20090202483-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | PKM 3874/4885ALDH1A1 1144/4885GRM5 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.